XEN凝胶支架植入眼部瘢痕性类天疱疮患者体内。
Implantation of XEN gel stent in a patient with ocular cicatricial pemphigoid.
作者信息
Zhou Yujia, Philip Andrew M, Chikovsky Max N, Nolan John, Anesi Stephen D
机构信息
The Ocular Immunology and Uveitis Foundation, Waltham, MA, USA.
Massachusetts Eye Research and Surgery Institution, Waltham, MA, USA.
出版信息
Am J Ophthalmol Case Rep. 2023 Jan 18;29:101801. doi: 10.1016/j.ajoc.2023.101801. eCollection 2023 Mar.
PURPOSE
Herein, we report a case of XEN gel stent implantation in a patient with ocular cicatricial pemphigoid that successfully reduced glaucoma topical medication at one year.
OBSERVATIONS
A 76-year-old male patient presented with severe ocular cicatricial pemphigoid and advanced glaucoma who required several topical medications to control intraocular pressure. Despite successful reduction of ocular inflammation with immunomodulatory therapy, his topical medication regimen prevented total remission of ocular inflammation. One year after XEN gel stent implantation, his intraocular pressures were controlled without any topical medication, and he had no ocular inflammation off any immunomodulatory therapy.
CONCLUSIONS AND IMPORTANCE
The XEN gel stent represents a useful intervention for glaucoma treatment even in the setting of severe ocular surface disease and can improve outcomes for concurrent inflammatory and glaucomatous pathology.
目的
在此，我们报告一例在患有眼部瘢痕性类天疱疮的患者中植入XEN凝胶支架的病例，该患者在一年时成功减少了青光眼局部用药。
观察结果
一名76岁男性患者患有严重的眼部瘢痕性类天疱疮和晚期青光眼，需要多种局部用药来控制眼压。尽管通过免疫调节疗法成功减轻了眼部炎症，但他的局部用药方案仍无法使眼部炎症完全缓解。植入XEN凝胶支架一年后，他的眼压在未使用任何局部用药的情况下得到控制，并且在未进行任何免疫调节治疗的情况下没有眼部炎症。
结论及意义
XEN凝胶支架即使在严重眼表疾病的情况下，也是一种用于青光眼治疗的有用干预措施，并且可以改善并发炎症和青光眼病理状况的治疗效果。
Zotero 插件